US FDA extends Gestiva review for preterm birth
This article was originally published in Scrip
The US FDAhas extended by three months its review of Hologic/KV Pharmaceutical's long-acting progesterone Gestiva to prevent preterm delivery. The new user fee date is January 25th. The NDA for Gestiva (17 alpha-hydroxyprogesterone caproate injection, or 17P) was initiated by Adeza Biomedical, which was acquired by Cytyc Corporation in April 2007. Later that year Hologic acquired the rights. In January, Hologic announced it sold the rights to KV upon approval of the pending NDA. In 2006 an FDA advisory panel recommended licensure for preventing preterm delivery, and the agency subsequently deemed Gestiva approvable pending an additional animal study and certain other conditions. If approved Gestiva would become the first FDA-licensed product for preventing preterm birth. A citizen's petition filed last year seeks to rescind the drug's orphan designation based upon 17P's longstanding availability and use in this indication.
You may also be interested in...
COVID-19 Vaccines: ACIP’s Allocation Proposal Prioritizes Long-Term Care Residents, Essential Workers
First group to receive vaccine would comprise health care personnel and residents of long-term care facilities; next in line are non-health care essential workers, who would take priority over adults with high-risk medical conditions and those ages 65 years and older, according to the CDC advisory committee’s proposed allocation framework.
Although US FDA wants sponsors to maintain blinded Phase III follow-up as long as possible after emergency use authorization or licensure, vaccine researcher Larry Corey says it will become ‘untenable’ to keep individuals in placebo arm once they qualify for vaccine access under the allocation framework.
Industry principles for enhancing diversity in clinical trials call for use of digital data collection tools and flexible scheduling of study site visits to reduce barriers to enrollment, as well as greater involvement of under-represented communities in the trial design planning process and recruitment of investigators with diverse ethnic and racial backrounds.